First Time Loading...

Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 2.74 USD -2.49% Market Closed
Updated: Apr 27, 2024

Profitability Summary

Mereo Biopharma Group PLC's profitability score is 21/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score
21/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Mereo Biopharma Group PLC

Revenue
7.1m GBP
Cost of Revenue
-1.9m GBP
Gross Profit
5.3m GBP
Operating Expenses
-36.9m GBP
Operating Income
-31.7m GBP
Other Expenses
5.6m GBP
Net Income
-26.1m GBP

Margins Comparison
Mereo Biopharma Group PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
384.3m USD
74%
-444%
-366%
US
Abbvie Inc
NYSE:ABBV
281.9B USD
66%
30%
9%
US
Amgen Inc
NASDAQ:AMGN
144.5B USD
70%
29%
24%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
87%
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.6B USD
86%
32%
30%
AU
CSL Ltd
ASX:CSL
132B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81.5B USD
78%
34%
21%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Moderna Inc
NASDAQ:MRNA
41.2B USD
31%
-62%
-69%
US
Biogen Inc
NASDAQ:BIIB
30.3B USD
74%
21%
12%
KR
Celltrion Inc
KRX:068270
36.6T KRW
48%
30%
25%
Country UK
Market Cap 384.3m USD
Gross Margin
74%
Operating Margin
-444%
Net Margin
-366%
Country US
Market Cap 281.9B USD
Gross Margin
66%
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 144.5B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
24%
Country US
Market Cap 102.4B USD
Gross Margin
87%
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 96.6B USD
Gross Margin
86%
Operating Margin
32%
Net Margin
30%
Country AU
Market Cap 132B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81.5B USD
Gross Margin
78%
Operating Margin
34%
Net Margin
21%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 41.2B USD
Gross Margin
31%
Operating Margin
-62%
Net Margin
-69%
Country US
Market Cap 30.3B USD
Gross Margin
74%
Operating Margin
21%
Net Margin
12%
Country KR
Market Cap 36.6T KRW
Gross Margin
48%
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Mereo Biopharma Group PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
384.3m USD
-41%
-28%
-47%
-90%
US
Abbvie Inc
NYSE:ABBV
281.9B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
144.5B USD
136%
8%
13%
11%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.6B USD
16%
13%
15%
32%
AU
CSL Ltd
ASX:CSL
132B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81.5B USD
26%
9%
18%
14%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Moderna Inc
NASDAQ:MRNA
41.2B USD
-29%
-21%
-23%
-41%
US
Biogen Inc
NASDAQ:BIIB
30.3B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
36.6T KRW
5%
4%
6%
4%
Country UK
Market Cap 384.3m USD
ROE
-41%
ROA
-28%
ROCE
-47%
ROIC
-90%
Country US
Market Cap 281.9B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 144.5B USD
ROE
136%
ROA
8%
ROCE
13%
ROIC
11%
Country US
Market Cap 102.4B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 96.6B USD
ROE
16%
ROA
13%
ROCE
15%
ROIC
32%
Country AU
Market Cap 132B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81.5B USD
ROE
26%
ROA
9%
ROCE
18%
ROIC
14%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 41.2B USD
ROE
-29%
ROA
-21%
ROCE
-23%
ROIC
-41%
Country US
Market Cap 30.3B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 36.6T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More